Emerald Advisers’s AbbVie ABBV Stock Holding History

Emerald Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,418	Closed	-$356K	–	251
2019 Q1	$356K	Hold	4,418	–	–	0.01%	211
2018 Q4	$407K	Hold	4,418	–	–	0.02%	200
2018 Q3	$418K	Buy	4,418 +1,291	+41%	+$122K	0.02%	216
2018 Q2	$290K	Buy	+3,127	New	+$305K	0.01%	230
2014 Q4	–	Sell	-3,535	Closed	-$204K	–	338
2014 Q3	$204K	Sell	3,535 -1,640	-32%	-$91K	0.01%	331
2014 Q2	$292K	Sell	5,175 -490	-9%	-$25.7K	0.02%	316
2014 Q1	$291K	Sell	5,665 -1,314	-19%	-$66.4K	0.02%	319
2013 Q4	$369K	Sell	6,979 -394	-5%	-$19.4K	0.02%	298
2013 Q3	$330K	Buy	+7,373	New	+$327K	0.02%	307

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Emerald Advisers's ABBV Position: Q2 2019 in Review

Emerald Advisers sold out of AbbVie (ABBV) in Q2 2019, closing a stake of 4,418 shares — an estimated $356K sold.

Emerald Advisers first reported a position in ABBV in Q3 2013 and held it in 9 quarters. The position peaked at $418K in Q3 2018. 2,020 funds tracked by Wall St. Rank hold ABBV as of Q2 2019.

Emerald Advisers reported no remaining AbbVie position as of Q2 2019 after selling out during the quarter.
Emerald Advisers sold 4,418 AbbVie shares in Q2 2019, an estimated $356K.
Emerald Advisers first reported a position in AbbVie in Q3 2013 and held it in 9 quarters.
Emerald Advisers's AbbVie position peaked at $418K in Q3 2018.
2,020 funds tracked by Wall St. Rank held AbbVie as of Q2 2019.

Based on Emerald Advisers's 13F filing for Q2 2019, filed 31 Jul 2019.